Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2020 - 08 - 15
点击次数: 0
Positions: Vice President
Company: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
个人简介:
Mr. Li Dongming, born in September 1969. Mr. Li Dongming successively served as technician trainee, deputy director, director and concurrently served as both the assistant to the plant manager and director in the workshop of Shanghai Yan’an Pharmaceutical Plant from August 1989 to March 1998. He concurrently served as the deputy general manager and director of human resources department in Shanghai Yan’an Wanxiang Pharmaceutical Co., Ltd. from March 1998 to January 2002. He was the vice plant manager in Shanghai Sine Pharmaceuticals, currently known as Shanghai SPH Sine Pharmaceutical Laboratories Co., Ltd. from January 2002 to October 2003. He successively served as the strategic director of the strategy and investment committee office under the board of directors, as well as the vice president of the OTC sales business department of Shanghai Pharmaceuticals (Group) Limited from October 2003 to April 2008. He concurrently served as the director and deputy general manager of Shanghai Roche Pharmaceutical Co., Ltd. from May 2008 to November 2013. He concurrently served as the director and general manager of Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd. from November 2013 to September 2016. He also concurrently served as the director and general manager of Shanghai Pharmaceutical Group Pharma Sales Co., Ltd. from September 2016 to April 2017. He has been serving as the Co-president of Shanghai Fosun Pharmaceutical Development Co., Ltd.  since April 2017. Mr. Li Dongming obtained his bachelor’s degree in science from Fudan University in July 1989.
发布时间: 2020 - 05 - 27
点击次数: 0
Positions: General Manager
Company: Shandong Xinhua Pharmaceutical Co., Ltd.
个人简介:
Du Deping, Male, born in August 1969, Doctor degree, graduated from Ocean University of China, Professor, current General Manager of Shandong Xinhua Pharmaceutical Co., Ltd.Xinhua Pharmaceutical Co.,ltd was established in Jiaodong Anti-Japanese Base in 1943. It is the first chemical synthesis pharmaceutical company in China and now is important global production and export base for Antipyretic and Analgesic, Cardio-Cerebrovascular, Central Nervous and other drugs. Xinhua Pharm is listed in Shenzhen and Hongkong exchange stock markets, developed three pillar industries of Pharmaceutical Preparations, APIs, and Pharmaceutical Intermediates, with an annual output of 35,000 tons of APIs, 8 billion tablets, 1 billion injections, and 1.5 billion capsules, with total assets of RMB 6 billion and annual operations revenue of RMB 6 billion.
发布时间: 2020 - 08 - 15
点击次数: 0
Positions: Principle scientist /Engineering & technology
Company: Apeloa Pharmaceutical Co., Ltd.
个人简介:
14 years’ experience in Bayer as senior technology development engineer and project manager, responsible for technology package development based on continuous process, de-bottlenecking, technology solution for plant, R&D project management of pharmaceutical and crop-products.
发布时间: 2020 - 05 - 27
点击次数: 0
Positions: Vice President, President of BioMedicine Development and Business Division
Company: Jiangsu Hengrui Medicine Co.,Ltd.
个人简介:
江苏恒瑞医药股份有限公司副总经理,恒瑞生物医药发展事业部总经理。北京大学化学系学士,美国罗格斯大学生物化学博士,曾师从诺贝尔奖获得者Gobind Khorana教授所在的麻省理工学院,从事膜蛋白结构及功能研究,完成3年半的博士后研究。在国外有影响力的期刊发表诸多学术论文。刘洵博士拥有20多年的生物制药研发,临床和商业规模生产经验,在制药领域涉及很多新药研发以及工艺优化的研究,包括从临床前的研究开发直至商业生产。 他曾在美国国立卫生研究院(NIH)疫苗研究中心任职。负责大分子药物开发和临床药物生产,期间带领并完成多个生物药物的临床申报, 被授予研究院终身研究员。 在加入美国国立卫生研究院(NIH)疫苗研究中心之前,刘洵博士曾担任拜耳(Bayer)医疗药物公司的首席工程师,也是拜耳销售最好大分子药物(Kogenate FS)的商业生产专家。在他职业生涯的早期阶段,他任职于美国安进(Amgen)公司,致力于生物药品制剂和给药装置的商业化开发,及三期临床生产的技术转移。为安进公司目前已上市药物(Prolia,Xgeva)三期临床生产以及商业开展做出贡献。